STAGE III URETER CANCER AJCC V8
Clinical trials for STAGE III URETER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III URETER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III URETER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: STAGE III URETER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 13:08 UTC
-
New combo aims to stall advanced bladder cancer
Disease control OngoingThis study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…
Matched conditions: STAGE III URETER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE III URETER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC